Key result
Concurrent use of biomedicine and Korean Medicine was reported by 6.27% of hypertension patients, with obesity (OR 1.417) and experience of sickness (OR 2.323) identified as significant determinants.
Why the study?
To assess the utilization and determinants of concurrent biomedicine and Korean Medicine use among patients with hypertension.
What are the utilization rate and determinants of concurrent use of biomedicine and Korean Medicine among hypertension patients?
Cross-Sectional (n=3,320)
What are the utilization rate and determinants of concurrent use of biomedicine and Korean Medicine among hypertension patients?
A small proportion (6.27%) of Korean hypertension patients concurrently use biomedicine and Korean Medicine, with obesity and recent sickness experience being significant predictors of concurrent use.
Low concurrent use should not change hypertension practice; leaves open prospective evaluation of obesity and sickness as integration determinants.
BACKGROUND: This study assessed the utilization of biomedicine and Korean Medicine (KM) among hypertension patients. METHODS: The study was a cross-sectional analysis conducted using the Korean National Health and Nutrition Examination Survey (KNHANES), which is a nationwide survey conducted every year for a representative Korean population. The use of outpatient healthcare services for hypertension patients was analyzed, and the usage determinants adjusted by the demographic and health status variables were identified. A chi-square test and logistic regression analysis were used for statistical analysis using R (version 3.6.0). RESULTS: Among 3320 hypertension patients, 208 patients (6.27%, Weighted%: 5.99%) used the biomedicine and KM concurrently. Multivariable regression analyses revealed hypertension patients who were obese (OR: 1.417, CI: 1.007-1.995) and had an experience of sickness (OR: 2.323, CI: 1.561-3.457) to be more likely to use biomedicine and KM concurrently. CONCLUSION: The utilization rate and determinants of the concurrent use of biomedicine and KM were identified in patients with hypertension. Although the overall usage rate was not high, the health care patterns of healthcare consumers need to be understood. Therefore, further studies on its effectiveness and safety are recommended.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) conducted a cross-sectional in Hypertension (n=3,320). Concurrent use of biomedicine and Korean Medicine vs. Biomedicine monotherapy was evaluated on Determinant of concurrent use: experience of sickness (OR 2.323, 95% CI 1.561-3.457). Concurrent use of biomedicine and Korean Medicine was reported by 6.27% of hypertension patients, with obesity (OR 1.417) and experience of sickness (OR 2.323) identified as significant determinants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: